_256_384.jpg)
News | September 17, 2021
Promising prospects for Indian pharma: CLSA
CLSA, a capital market and investment group organised an Investors’ Forum where five Indian pharma companies participated. Excerpts from the report
CLSA, a capital market and investment group organised an Investors’ Forum where five Indian pharma companies participated. Excerpts from the report
The company will manufacture the products at its US FDA approved oral dosage facility at Goa in India
The company has decided to transfer our rights in relation to the lodex and Ostocalcium brands to GlaxoSmithKline Asia Private Limited
Revenue from operations for the year ended March 31, 2021 is ?2,239 crore
Lupin will provide five lakh LupiSafe hand sanitizers to policemen and frontline workers deployed at strategic locations
PEL will explore the PLI scheme and apply if its beneficial.
_256_384.jpg)
The company expects to generate an EBITDA margin before special items of around 27 percent in 2021.
ranules now has a total of 38 ANDA approvals from US FDA.
Be One is a 100% Ayurvedic health and wellness supplement.
Subscribe To Our Newsletter & Stay Updated
